

Table S8. Function and effect of aberrations of differentially expressed genes between Cribriform and Noncribriform

Gene	Gene Name	logFC	FDR	Function/Effect of aberration in PCa	Reference
Tumor suppressor Gene (TSG), down-regulated in ICC					
PAGE4	P Antigen Family, Member 4	-1.646786	4.30E-07	Normally protects against ROS & DNA damage Reduced expression increases NAD for cellular metabolism Associated with aggressive PCa	(1)
CD38	CD38 Molecule	-1.470986	3.39E-04		(2)
SRD5A2	Steroid 5 Alpha-Reductase 2	-1.275225	2.46E-06	Reduced expression in metastasis	(3)
CYP27A1	Cytochrome P450 Family 27 Subfamily A Member 1	-1.073995	1.68E-06	Poor prognosis & associated with high grade PCa	(4)
CYP11A1	Cytochrome P450 Family 11 Subfamily A Member 1	-0.998918	1.05E-06	Reduced expression in metastasis. BCR	(3) (5)
COL4A6	Collagen Type IV Alpha 6	-0.993641	2.47E-05	Type IV collagen, component of BM. Metastasis and with poor prognosis	(6)
SLC18A2	Solute Carrier Family 18 Member A2	-0.952219	1.35E-03	Poor prognosis and BCR.	(7)
EPHA5	EPH Receptor A5	-0.949169	3.76E-03	Downregulated by methylation & associated with high stage and Gleason score.	(8)
CMTM5	CKLF Like MARVEL Transmembrane Domain Containing 5	-0.911282	3.35E-06	Normally inhibits HER2/neu. Tumor progression.	(9) (10)
AOX1	Aldehyde Oxidase 1	-0.870435	6.93E-05	Downregulated by methylation & associated with BCR	(11)
PTN	Pleiotrophin	-0.870397	3.97E-04	Normally suppresses angiogenesis & induce apoptosis.	(12)
HSD17B6	Hydroxysteroid 17-Beta Dehydrogenase 6	-0.854969	2.68E-03	Reduced expression in metastasis.	(3)
PITX2	Paired Like Homeodomain 2	-0.848037	3.63E-03	BCR	(13) (14)
ALDH1A2	Aldehyde Dehydrogenase 1 Family Member A2	-0.839478	3.96E-05	Early event in prostate cancer	(15) (16)
MT1H	Metallothionein 1H	-0.824217	2.25E-03	Poor prognosis	(17)
MYL9	Myosin Light Chain 9	-0.808159	3.39E-05	Poor prognosis & BCR	(18)
FLNA	Filamin A	-0.798692	1.48E-05	Reduced expression in higher grade, stage & metastasis	(19)
GSTM2	Glutathione S-Transferase Mu 2	-0.797476	5.42E-05	Downregulation by methylation & associated with tumor development	(20)
Oncogenes, down-regulated in ICC					
CNTN1	Contactin 1	-0.777144	8.05E-04	Overexpression promotes tumor progression & metastasis	(21)
PCOTH	Prostate Collagen Triple Helix	-1.034192	1.11E-02	Enhances tumor growth & survival	(22)
L1CAM	L1 Cell Adhesion Molecule	-0.899279	1.37E-03	Reduced expression in preclinical studies results in cell cycle arrest, MMP-2 and MMP-9 inhibition & NF- κ B activation.	(23)
SCIN	Scinderin	-0.851501	1.09E-03	Normally regulates cell cycle genes	(24)
FGF10	Fibroblast Growth Factor 10	-0.837927	2.31E-05	Tumor multifocality & increased AR	(25)
Oncogenes, up-regulated in ICC					
DNAH8	Dynein Axonemal Heavy Chain 8	1.015575	4.88E-03	Expressed with metastasis & poor prognosis Enhances PCa growth & survival.	(26)
EN2	Engrailed Homeobox 2	0.9718	8.74E-04	As a biomarker in urine; detected in 70–85% of PCa & correlated with tumor volume	(27) (28)

MELK	Maternal Embryonic Leucine Zipper Kinase	0.883624	6.12E-06	Expressed in high risk tumors	(29)
RFX6	Regulatory Factor X6	0.83381	1.12E-02	Tumor progression, metastasis and BCR	(30)
BUB1	Budding Uninhibited By Benzimidazoles 1	0.791829	3.96E-05	Tumor progression & BCR	(31)
BIRC5*	Baculoviral IAP Repeat Containing 5	0.767755	2.47E-05	Potential predictor for tumor metastasis	(32)
RRM2	Ribonucleotide Reductase Regulatory Subunit M2	0.766402	2.47E-05	Prognostically superior to clinicopathologic parameters	(33)
KIF14	Kinesin Family Member 14	0.76265	2.41E-05	Expression associated with poor prognosis	(34)
PLK1*	Polo Like Kinase 1	0.754486	1.22E-05	Overexpression correlated positively with GS and CRPC	(35) (36)
TOP2A	Topoisomerase (DNA) II Alpha	0.751979	4.37E-05	BCR	(37)
CDC20	Cell Division Cycle 20	0.748226	2.34E-05	Metastatic CRPC and BCR.	(38)
UBE2C	Ubiquitin Conjugating Enzyme E2 C	0.744696	1.01E-04	CRPC	(39)
MNX1	Motor Neuron And Pancreas Homeobox 1	0.731781	1.93E-02	Overexpressed in aggressive PCa by activating AKT & AR signaling (especially African Americans)	(40)
CDC25C	Cell Division Cycle 25C	0.722864	2.07E-04	Overexpression with poor prognosis and BCR	(41)
HMMR	Hyaluronan Mediated Motility Receptor	0.710076	1.20E-04	Poor prognosis, CRPC & metastasis by enhancing cell motility & mitotic spindle integrity.	(42)
TPX2*	PX2, Microtubule Nucleation Factor NIMA (Never In Mitosis Gene A)-Related Kinase 2	0.709579	2.04E-05	BCR, high grade in younger age.	(43)
NEK2	Cyclin Dependent Kinase 2	0.706773	5.76E-04	Chromosomal instability. Associated with high stage & GS.	(44)
CDK1	Cyclin Dependent Kinase 1	0.693504	3.76E-05	BCR.	(45)
CDC45*	Cell Division Cycle 45	0.687727	7.78E-04	Predictor for metastasis	(32)
AURKB	Aurora Kinase B	0.680417	2.07E-04	CRPC	(46)
CENPF	Centromere Protein F	0.673381	7.58E-05	Poor prognosis & metastasis	(47)
ASPM	Abnormal Spindle Microtubule Assembly	0.663055	5.91E-04	BCR, poor prognosis & metastasis	(48)
CEP55	Centrosomal Protein 55	0.656456	2.06E-04	Risk of recurrence	(49)
ANLN	Anillin Actin Binding Protein	0.655225	2.83E-04	CRPC	(50)
PBK*	PDZ Binding Kinase NUF2, NDC80	0.641457	1.57E-03	Poor prognosis, CRPC & metastasis.	(51)
NUF2	Kinetochore Complex Component	0.637019	4.04E-04	Risk of recurrence	(49)
FOXM1*	Forkhead Box M1	0.636058	7.58E-05	Expressed in PCa	(52)
NUSAP1	Nucleolar & Spindle associated Protein 1	0.629991	1.34E-04	Enhances tumor invasion, migration & metastasis	(53)
PTTG1*	Pituitary Tumor-Transforming Gene 1 Protein	0.619099	1.49E-04	Enhances tumor proliferation	(54)
KIFC1	Kinesin Family Member C1	0.590184	6.62E-05	Poor prognosis	(55)
SPAG5	Sperm Associated Antigen 5	0.588704	2.67E-05	BCR, poor prognosis & metastasis	(56)
PTK6	Protein Tyrosine Kinase 6	0.582391	3.22E-02	Enhances EMT by activating AKT signaling. Poor prognosis.	(57)
CDCA3*	Cell Division Cycle Associated 3	0.549563	3.47E-04	Enhances tumor progression by activating CDCA3	(58)
SKA1	Spindle & Kinetochore-Associated Protein 1	0.533576	7.33E-04	Tumor progression.	(59)

TK1	Thymidine Kinase 1	0.529587	2.16E-04	Recurrence and lethal outcome	(60)
MLF1IP	myeloid leukemia factor 1 interacting protein	0.525694	1.06E-04	Enhances cell proliferation by inhibiting the apoptosis	(61)
UHRF1*	Ubiquitin Like With PHD & Ring Finger Domains 1	0.519142	2.55E-03	BCR	(62) (63)
UBE2T	Ubiquitin Conjugating Enzyme E2 T	0.510836	1.08E-04	Poor prognosis & metastasis	(64)
FAM72B	Family With Sequence Similarity 72 Member B	0.509938	5.96E-04	Predictor for high risk PCa BCR	(65)
TACC3	Transforming Acidic Coiled-Coil Containing Protein 3	0.505073	1.57E-04	BCR, high GS & metastasis. Activation of Wnt/β-catenin signaling	(66)

NOTE: Genes associated with metastasis highlighted in boldface. * potential targets for PCa therapy

Abbreviations: PCa, prostate cancer; GS, Gleason score; ROS, reactive oxygen species; BCR, Biochemical recurrence; MMP-2, Matrix Metallopeptidase 2; MMP-9, Matrix Metallopeptidase 9; BM, Basement membrane; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B; CRPC, Castration Resistant Prostate Cancer.

References

1. Kulkarni P, Dunker AK, Weninger K, Orban J. Prostate-associated gene 4 (PAGE4), an intrinsically disordered cancer/testis antigen, is a novel therapeutic target for prostate cancer. *Asian journal of andrology* **2016**;18:695-703
2. Liu X, Grogan TR, Hieronymus H, Hashimoto T, Mottahedeh J, Cheng D, *et al.* Low CD38 identifies progenitor-like inflammation-associated luminal cells that can initiate human prostate cancer and predict poor outcome. *Cell reports* **2016**;17:2596-606
3. Jernberg E, Thysell E, Bovinder Ylitalo E, Rudolfsson S, Crnalic S, Widmark A, *et al.* Characterization of Prostate Cancer Bone Metastases According to Expression Levels of Steroidogenic Enzymes and Androgen Receptor Splice Variants. *PloS one* **2013**;8:e77407
4. Alfaqih MA, Nelson ER, Liu W, Safi R, Jasper JS, Macias E, *et al.* CYP27A1 Loss Dysregulates Cholesterol Homeostasis in Prostate Cancer. *Cancer research* **2017**;77:1662-73
5. Horning AM, Awe JA, Wang CM, Liu J, Lai Z, Wang VY, *et al.* DNA methylation screening of primary prostate tumors identifies SRD5A2 and CYP11A1 as candidate markers for assessing risk of biochemical recurrence. *The Prostate* **2015**;75:1790-801
6. Varisli L. Identification of New Genes Downregulated in Prostate Cancer and Investigation of Their Effects on Prognosis. 2013.
7. Haldrup C, Lynnerup A-S, Storebjerg TM, Vang S, Wild P, Visakorpi T, *et al.* Large-scale evaluation of SLC18A2 in prostate cancer reveals diagnostic and prognostic biomarker potential at three molecular levels. *Molecular Oncology* **2016**;10:825-37
8. Li S, Zhu Y, Ma C, Qiu Z, Zhang X, Kang Z, *et al.* Downregulation of EphA5 by promoter methylation in human prostate cancer. *BMC cancer* **2015**;15:18
9. Xu T, Li J, Xiao YB, Liu ZH, Li Q, Wang XF. [CMTM5 inhibits the tumor cell behavior of prostate cancer by downregulation of HER2]. Beijing da xue xue bao Yi xue ban = Journal of Peking University Health sciences **2010**;42:386-90
10. Xiao Y, Yuan Y, Zhang Y, Li J, Liu Z, Zhang X, *et al.* CMTM5 is reduced in prostate cancer and inhibits cancer cell growth in vitro and in vivo. *Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico* **2015**;17:431-7
11. Haldrup C, Mundbjerg K, Vestergaard EM, Lamy P, Wild P, Schulz WA, *et al.* DNA methylation signatures for prediction of biochemical recurrence after radical prostatectomy of clinically localized prostate cancer. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* **2013**;31:3250-8
12. Tsirmoula S, Dimas K, Hatziapostolou M, Lamprou M, Ravazoula P, Papadimitriou E. Implications of pleiotrophin in human PC3 prostate cancer cell growth in vivo. *Cancer science* **2012**;103:1826-32
13. Vinarskaja A, Schulz WA, Ingenwerth M, Hader C, Arsov C. Association of PITX2 mRNA down-regulation in prostate cancer with promoter hypermethylation and poor prognosis. *Urologic oncology* **2013**;31:622-7
14. Litovkin K, Joniau S, Lerut E, Laenen A, Gevaert O, Spahn M, *et al.* Methylation of PITX2, HOXD3, RASSF1 and TDRD1 predicts biochemical recurrence in high-risk prostate cancer. *Journal of cancer research and clinical oncology* **2014**;140:1849-61
15. Kim H, Lapointe J, Kaygusuz G, Ong DE, Li C, van de Rijn M, *et al.* The Retinoic Acid Synthesis Gene ALDH1a2 Is a Candidate Tumor Suppressor in Prostate Cancer. *Cancer research* **2005**;65:8118
16. Touma SE, Perner S, Rubin MA, Nanus DM, Gudas LJ. Retinoid metabolism and ALDH1A2 (RALDH2) expression are altered in the transgenic adenocarcinoma mouse prostate model. *Biochemical pharmacology* **2009**;78:1127-38

17. Han YC, Zheng ZL, Zuo ZH, Yu YP, Chen R, Tseng GC, *et al.* Metallothionein 1 h tumour suppressor activity in prostate cancer is mediated by euchromatin methyltransferase 1. *The Journal of pathology* **2013**;230:184-93
18. Huang YQ, Han ZD, Liang YX, Lin ZY, Ling XH, Fu X, *et al.* Decreased expression of myosin light chain MYL9 in stroma predicts malignant progression and poor biochemical recurrence-free survival in prostate cancer. *Medical oncology (Northwood, London, England)* **2014**;31:820
19. Sun G, Lu Y, Zhang J, Hu W. Filamin A regulates MMP-9 expression and suppresses prostate cancer cell migration and invasion. *Tumor Biology* **2014**;35:3819-26
20. Ashour N, Angulo JC, Andrés G, Alelú R, González-Corpas A, Toledo MV, *et al.* A DNA hypermethylation profile reveals new potential biomarkers for prostate cancer diagnosis and prognosis. *The Prostate* **2014**;74:1171-82
21. Yan J, Ojo D, Kapoor A, Lin X, Pinthus JH, Aziz T, *et al.* Neural cell adhesion protein CNTN1 promotes the metastatic progression of prostate cancer. *Cancer research* **2016**;76:1603-14
22. Anazawa Y, Nakagawa H, Furihara M, Ashida S, Tamura K, Yoshioka H, *et al.* PCOTH, a novel gene overexpressed in prostate cancers, promotes prostate cancer cell growth through phosphorylation of oncoprotein TAF-I β /SET. *Cancer research* **2005**;65:4578-86
23. Sung S-Y, Wu I-H, Chuang P-H, Petros JA, Wu H-C, Zeng H-J, *et al.* Targeting L1 cell adhesion molecule expression using liposome-encapsulated siRNA suppresses prostate cancer bone metastasis and growth. *Oncotarget* **2014**;5:9911
24. Wang D, Sun S-Q, Yu Y-H, Wu W-Z, Yang S-L, Tan J-M. Suppression of SCIN inhibits human prostate cancer cell proliferation and induces G0/G1 phase arrest. *International journal of oncology* **2014**;44:161-6
25. Memarzadeh S, Xin L, Mulholland DJ, Mansukhani A, Wu H, Teitell MA, *et al.* Enhanced paracrine FGF10 expression promotes formation of multifocal prostate adenocarcinoma and an increase in epithelial androgen receptor. *Cancer cell* **2007**;12:572-85
26. Wang Y, Ledet RJ, Imberg-Kazdan K, Logan SK, Garabedian MJ. Dynein axonemal heavy chain 8 promotes androgen receptor activity and associates with prostate cancer progression. *Oncotarget* **2016**;7:49268
27. Bose SK, Bullard RS, Donald CD. Oncogenic role of engrailed-2 (en-2) in prostate cancer cell growth and survival. *Translational oncogenomics* **2008**;3:37
28. Pandha H, Sorensen KD, Orntoft TF, Langley S, Hoyer S, Borre M, *et al.* Urinary engrailed-2 (EN2) levels predict tumour volume in men undergoing radical prostatectomy for prostate cancer. *BJU international* **2012**;110:E287-92
29. Kuner R, Fälth M, Pressinotti NC, Bräse JC, Puig SB, Metzger J, *et al.* The maternal embryonic leucine zipper kinase (MELK) is upregulated in high-grade prostate cancer. *Journal of molecular medicine* **2013**;91:237-48
30. Huang Q, Whittington T, Gao P, Lindberg JF, Yang Y, Sun J, *et al.* A prostate cancer susceptibility allele at 6q22 increases RFX6 expression by modulating HOXB13 chromatin binding. *Nature genetics* **2014**;46:126-35
31. Fu X, Chen G, Cai Z-d, Wang C, Liu Z-z, Lin Z-y, *et al.* Overexpression of BUB1B contributes to progression of prostate cancer and predicts poor outcome in patients with prostate cancer. *OncoTargets and therapy* **2016**;9:2211
32. Li HY, Jin N, Han YP, Jin XF. Pathway crosstalk analysis in prostate cancer based on protein-protein network data. *Neoplasma* **2017**;64:22-31
33. Huang Y, Liu X, Wang Y-H, Yeh S-D, Chen C-L, Nelson RA, *et al.* The prognostic value of ribonucleotide reductase small subunit M2 in predicting recurrence for prostate cancers. 2014. Elsevier. p 51. e9-. e19.
34. Zhang Y, Yuan Y, Liang P, Zhang Z, Guo X, Xia L, *et al.* Overexpression of a novel candidate oncogene KIF14 correlates with tumor progression and poor prognosis in prostate cancer. *Oncotarget* **2017**;8:45459
35. Weichert W, Schmidt M, Gekeler V, Denkert C, Stephan C, Jung K, *et al.* Polo-like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades. *The Prostate* **2004**;60:240-5

36. Li J, Karki A, Hodges KB, Ahmad N, Zoubeidi A, Strebhardt K, *et al.* Cotargeting Polo-Like Kinase 1 and the Wnt/beta-Catenin Signaling Pathway in Castration-Resistant Prostate Cancer. *Molecular and cellular biology* **2015**;35:4185-98
37. de Resende MF, Vieira S, Chinen LT, Chiappelli F, da Fonseca FP, Guimaraes GC, *et al.* Prognostication of prostate cancer based on TOP2A protein and gene assessment: TOP2A in prostate cancer. *Journal of translational medicine* **2013**;11:36
38. Mao Y, Li K, Lu L, Si-Tu J, Lu M, Gao X. Overexpression of Cdc20 in clinically localized prostate cancer: Relation to high Gleason score and biochemical recurrence after laparoscopic radical prostatectomy. *Cancer biomarkers : section A of Disease markers* **2016**;16:351-8
39. Chen Z, Zhang C, Wu D, Chen H, Rorick A, Zhang X, *et al.* Phospho-MED1-enhanced UBE2C locus looping drives castration-resistant prostate cancer growth. *The EMBO journal* **2011**;30:2405-19
40. Zhang L, Wang J, Wang Y, Zhang Y, Castro P, Shao L, *et al.* MNX1 is oncogenically upregulated in African-American prostate cancer. *Cancer research* **2016**;76:6290-8
41. Ozen M, Ittmann M. Increased expression and activity of CDC25C phosphatase and an alternatively spliced variant in prostate cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research* **2005**;11:4701-6
42. Rizzardi AE, Vogel RI, Koopmeiners JS, Forster CL, Marston LO, Rosener NK, *et al.* Elevated HA and HMMR are associated with biochemical failure in patients with intermediate grade prostate tumors. *Cancer* **2014**;120:1800
43. Vainio P, Mpindi J-P, Kohonen P, Fey V, Mirtti T, Alanen KA, *et al.* High-throughput transcriptomic and RNAi analysis identifies AIM1, ERGIC1, TMED3 and TPX2 as potential drug targets in prostate cancer. *PloS one* **2012**;7:e39801
44. Zeng Y-R, Han Z-D, Wang C, Cai C, Huang Y-Q, Luo H-W, *et al.* Overexpression of NIMA-related kinase 2 is associated with progression and poor prognosis of prostate cancer. *BMC urology* **2015**;15:90
45. Willder J, Heng S, McCall P, Adams C, Tannahill C, Fyffe G, *et al.* Androgen receptor phosphorylation at serine 515 by Cdk1 predicts biochemical relapse in prostate cancer patients. *British journal of cancer* **2013**;108:139-48
46. Addepalli M, Ray K, Kumar B, Ramnath R, Rao H. RNAi-mediated knockdown of AURKB and EGFR shows enhanced therapeutic efficacy in prostate tumor regression. *Gene therapy* **2010**;17:352-9
47. Aytes A, Mitrofanova A, Lefebvre C, Alvarez MJ, Castillo-Martin M, Zheng T, *et al.* Cross-species regulatory network analysis identifies a synergistic interaction between FOXM1 and CENPF that drives prostate cancer malignancy. *Cancer cell* **2014**;25:638-51
48. Xie J-J, Zhuo Y-J, Zheng Y, Mo R-J, Liu Z-Z, Li B-W, *et al.* High expression of ASPM correlates with tumor progression and predicts poor outcome in patients with prostate cancer. *International urology and nephrology* **2017**;49:817-23
49. Shiraishi T, Terada N, Zeng Y, Suyama T, Luo J, Trock B, *et al.* Cancer/testis antigens as potential predictors of biochemical recurrence of prostate cancer following radical prostatectomy. *Journal of translational medicine* **2011**;9:153
50. Tamura K, Furihata M, Tsunoda T, Ashida S, Takata R, Obara W, *et al.* Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles. *Cancer research* **2007**;67:5117-25
51. Brown-Clay JD, Shenoy DN, Timofeeva O, Kallakury BV, Nandi AK, Banerjee PP. PBK/TOPK enhances aggressive phenotype in prostate cancer via β -catenin-TCF/LEF-mediated matrix metalloproteinases production and invasion. *Oncotarget* **2015**;6:15594
52. Cai Y, Balli D, Ustiyann V, Fulford L, Hiller A, Misetic V, *et al.* Foxm1 expression in prostate epithelial cells is essential for prostate carcinogenesis. *Journal of Biological Chemistry* **2013**;288:22527-41
53. Gordon CA, Gong X, Ganesh D, Brooks JD. NUSAP1 promotes invasion and metastasis of prostate cancer. *Oncotarget* **2017**;8:29935
54. Huang S, Liao Q, Li L, Xin D. PTTG1 inhibits SMAD3 in prostate cancer cells to promote their proliferation. *Tumor Biology* **2014**;35:6265-70

55. Sekino Y, Oue N, Shigematsu Y, Ishikawa A, Sakamoto N, Sentani K, *et al.* KIFC1 induces resistance to docetaxel and is associated with survival of patients with prostate cancer. 2017. Elsevier. p 31. e13-31. e20.
56. Zhang H, Li S, Yang X, Qiao B, Zhang Z, Xu Y. miR-539 inhibits prostate cancer progression by directly targeting SPAG5. *Journal of Experimental & Clinical Cancer Research* **2016**;35:60
57. Zheng Y, Wang Z, Bie W, Brauer PM, White BEP, Li J, *et al.* PTK6 activation at the membrane regulates epithelial–mesenchymal transition in prostate cancer. *Cancer research* **2013**;73:5426-37
58. Chen J, Zhu S, Jiang N, Shang Z, Quan C, Niu Y. HoxB3 promotes prostate cancer cell progression by transactivating CDCA3. *Cancer letters* **2013**;330:217-24
59. Li J, Xuan JW, Khatamianfar V, Valiyeva F, Moussa M, Sadek A, *et al.* SKA1 over-expression promotes centriole over-duplication, centrosome amplification and prostate tumourigenesis. *The Journal of pathology* **2014**;234:178-89
60. Rubicz R, Zhao S, April C, Wright JL, Kolb S, Coleman I, *et al.* Expression of cell cycle-regulated genes and prostate cancer prognosis in a population-based cohort. *The Prostate* **2015**;75:1354-62
61. Zhang L, Ji G, Shao Y, Qiao S, Jing Y, Qin R, *et al.* MLF1 interacting protein: a potential gene therapy target for human prostate cancer? *Medical Oncology* **2015**;32:4
62. Babbio F, Pistore C, Curti L, Castiglioni I, Kunderfranco P, Brino L, *et al.* The SRA protein UHRF1 promotes epigenetic crosstalks and is involved in prostate cancer progression. *Oncogene* **2012**;31:4878-87
63. Wan X, Yang S, Huang W, Wu D, Chen H, Wu M, *et al.* UHRF1 overexpression is involved in cell proliferation and biochemical recurrence in prostate cancer after radical prostatectomy. *Journal of Experimental & Clinical Cancer Research* **2016**;35:34
64. Wen M, Kwon Y, Wang Y, Mao J-H, Wei G. Elevated expression of UBE2T exhibits oncogenic properties in human prostate cancer. *Oncotarget* **2015**;6:25226-39
65. Rajan P, Stockley J, Sudbery IM, Fleming JT, Hedley A, Kalna G, *et al.* Identification of a candidate prognostic gene signature by transcriptome analysis of matched pre-and post-treatment prostatic biopsies from patients with advanced prostate cancer. *BMC cancer* **2014**;14:977
66. Li Q, Ye L, Guo W, Wang M, Huang S, Peng X. Overexpression of TACC3 is correlated with tumor aggressiveness and poor prognosis in prostate cancer. *Biochemical and Biophysical Research Communications* **2017**;486:872-8